Cancer is a disease characterized by abnormal cell growth. Cancer Immunotherapy is an immune response against cancer cells, by boosting the body’s natural immune system. Its main purpose is to stop the spreading of cancer, slow down the growth of cancer cells and improve the natural immunity.
Demand Scenario
The global cancer immunotherapy market was USD 57 billion in 2018 and is estimated to reach USD 151.89 billion by 2025 at a CAGR of 15.03% during the forecast period.
Growth by Region
North America dominates the global market for cancer immunotherapy followed by Europe. The global domination of North America is attributable to factors such as rising incidence of cancer, increasing ease of access to modern therapeutics, and rise in government investments for R&D and the healthcare reforms for the treatment of cancer. Europe is estimated to witness rapid growth during the forecast period owing to rapid adoption of advanced cancer therapeutics for effective cancer treatment.
Asia-Pacific will witness the fastest growth rate during the forecasted period owing to factors such as increase in pool of patient population, rise in prevalence of different types of cancer, and rise in government investments for R&D and the healthcare reforms for the treatment of cancer. Also rising mortality rate and presence of major market players with major investments is propelling the demand for immunotherapy in the region.
Drivers vs Constraints
Factors that drives the growth of the market includes rising incidence of cancer, technological advancements in treatment therapies, rising healthcare expenditure, increase in number of R&D for the treatment of cancer, and effectiveness of cancer immunotherapy for the treatment of wide range of cancers.
Also, the higher mortality rate and adverse effects associated with conventional chemotherapies and increase in number of approvals for new immunotherapeutic drugs is driving the global market. Shortage of experienced healthcare professionals, stringent government regulations, risk of side effects, lack of awareness among the population restrict the growth, challenges in clinical trials coupled with higher costs could hamper the growth of the market.
Industry Trends and Updates
In May 2018, Eli Lilly acquired ARMO BioSciences and its lead treatment candidate pegi lodecakin which is in Phase 3 trials. In November 2017, Biothera Pharmaceuticals, Inc announced its collaboration agreement with Genentech, Inc. for entering clinical trials.
In November 2017, GlaxoSmithKline received FDA approval of the development of blood cancer treatment. The US FDA granted the designation of Breakthrough Therapy.
Global Cancer Immunotherapy Market – by Type, Application, End User, Region - Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates (2018 - 2025)
1. Research Methodology
2. Executive Summary
3. Market Overview
3.1. Definition
3.2. Industry Value Chain Analysis
3.3. Porter's 5 Forces
3.4. Regulations
4. Market Dynamics
4.1. Introduction
4.2. Drivers
4.3. Constraints
4.4. Trends
5. Global Cancer Immunotherapy Market Segmentation, Forecasts and Trends - by Type
5.1. Monoclonal Antibodies
5.2. Immune Checkpoint Inhibitors
5.3. Immune System Modulators
5.4. Cancer Vaccines
5.5. Oncolytic Virus Immunotherapy
5.6. Others
6. Global Cancer Immunotherapy Market Segmentation, Forecasts and Trends - by Application
6.1. Lung
6.2. Breast
6.3. Colorectal
6.4. Melanoma
6.5. Prostate
6.6. Head & Neck
7. Global Cancer Immunotherapy Market Segmentation, Forecasts and Trends - by End User
7.1. Hospital
7.2. Clinics
8. Global Cancer Immunotherapy Market Segmentation, Forecasts and Trends - by Region
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.1.3. Mexico
8.2. Europe
8.2.1. UK
8.2.2. France
8.2.3. Germany
8.2.4. Italy
8.2.5. Spain
8.2.6. Others
8.3. Asia-Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. Others
8.4. Latin America
8.4.1. Brazil
8.4.2. Argentina
8.4.3. Others
8.5. Middle East and Africa
9. Competitive Intelligence
9.1. Company Market Share Analysis
9.2. Industry M&As, Consolidations
10. Company Profiles
10.1. Antigen Express Inc
10.2. Celldex Therapeutics
10.3. Dendreon Corp.
10.4. EMD Serono Inc
10.5. Eli Lilly and Co.
10.6. Genentech Inc
10.7. Genmab AS
10.8. GlaxoSmithKline
10.9. Gliknik Inc
10.10. GlobeImmune Inc
10.11. Heat Biologics Inc
10.12. Immatics Biotechnologies GmbH
10.13. Kite Pharma Inc
10.14. MabVax Therapeutics Holdings Inc
10.15. MedImmune LLC
10.16. Merck & Co., Inc
10.17. Morphotek Inc
10.18. NewLink Genetics Corp.
10.19. Northwest Biotherapeutics Inc
10.20. NovaRx Corp.
10.21. OSE Pharma SA
10.22. OncoPep Inc
10.23. Oncothyreon Inc
10.24. Oxford BioTherapeutics Ltd.
10.25. Pique Therapeutics
10.26. Regen Biopharma Inc
10.27. Roche Holdings Inc
10.28. TapImmune Inc
10.29. ThioLogics Ltd.
10.30. Transgene SA
10.31. Vaccinogen Inc
10.32. Viventia Biotechnologies Inc
10.33. Wilex AG
10.34. Ziopharm Oncology Inc
10.35. Astrazeneca plc.
10.36. Pfizer Inc.
10.37. Novartis AG
10.38. Advaxis Inc.
10.39. Bristol-Myers Squibb Company
10.40. Others
11. Investment Opportunities